K. Kostikas (Ioannina, Greece), A. Papi (Ferrara, Italy)
Late Breaking Abstract - Benralizumab treatment strongly reduces blood basophils in patients with severe eosinophilic asthma
H. Marchewski (Rostock, Germany), K. Bratke (Rostock, Germany), G. Schwefel (Rostock, Germany), J. Virchow (Rostock, Germany), M. Lommatzsch (Rostock, Germany)
|  |
Increased levels of human myeloperxidase (MPO) and neutrophil lipocalin (HNL/NGAL) in childhood asthma
C. Kim (Seoul, Republic of Korea), D. Shim (Seoul, Republic of Korea), M. Kim (Seoul, Republic of Korea), H. Cha (Seoul, Republic of Korea), S. Hwang (Seoul, Republic of Korea), J. Park (Seoul, Republic of Korea), K. Kim (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), M. Sohn (Seoul, Republic of Korea)
|  |
A polymorphism in DNASE1L3 is associated with severe asthma exacerbations in two-high risk populations for asthma
E. Herrera Luis (La Laguna, Spain), J. Perez-Garcia (La Laguna, Spain), N. Hernandez-Pacheco (La Laguna, Spain), S. Huntsman (San Francisco, United States of America), C. Eng (San Francisco, United States of America), E. Burchard (San Francisco, United States of America), F. Lorenzo-Diaz (La Laguna, Spain), M. Pino-Yanes (Madrid, Spain)
| |
Respiratory disease in a cohort of patients with primary antibody deficiency
P. Agarwal (Aberdeen, United Kingdom), D. Mullen (Aberdeen, United Kingdom), S. Azam (Aberdeen, United Kingdom), O. Dempsey (Aberdeen, United Kingdom), R. Herriot (Aberdeen, United Kingdom)
| |
Microbiome in lower respiratory tract of steroid- free patients with asthma
L. Yang (Chendu, China), B. Liu (Chendu, China), T. Liu (Chendu, China), J. Luo (Chendu, China), T. Huang (Chendu, China), C. Liu (Chendu, China)
| |
Treatment with Omalizumab in adults with severe allergic reduces Fc?I expression on dendritic cells and improves antiviral responses.
P. Wark (Newcastle, Australia), K. Nichol (Newcastle, Australia), D. Dorahy (Newcastle, Australia), A. Collison (Newcastle, Australia), J. Mattes (Newcastle, Australia)
| |
Relationship between CRTH2 mRNA expression in peripheral blood and IgE and eosinophil levels in adult patients with asthma
I. Dávila (Salamanca, Spain), A. García-Sánchez (Salamanca, Spain), M. Estravís (Salamanca, Spain), A. Landeira-Viñuela (Salamanca, Spain), A. Iribarren-López (Salamanca, Spain), E. Moreno-Jiménez (Salamanca, Spain), C. Martín-García (Salamanca, Spain), E. Moreno (Salamanca, Spain), C. Sanz (Salamanca, Spain), M. Isidoro-García (Salamanca, Spain)
| |
Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Asthma by Immunoglobin E Levels at Baseline
W. Carr (Mission Viejo, United States of America), D. Jackson (London, United Kingdom), J. Corren (Los Angeles, United States of America), K. Bergmann (Berlin, Germany), M. Rice (Cambridge, United States of America), Y. Deniz (Tarrytown, United States of America), P. Rowe (Bridgewater, United States of America), N. Amin (Tarrytown, United States of America), A. Teper (Bridgewater, United States of America)
| |
The German Severe Asthma Registry: FeNO values correlate with medical therapy, quality of life and smoking
C. Bal (Vienna, Austria), M. Idzko (Vienna, Austria), S. Škrgat (Golnik, Slovenia), A. Koch (Friedberg, Germany), C. Schulz (Regensburg, Germany), E. Hamelmann (Bielefeld, Germany), R. Buhl (Mainz, Germany), S. Korn (Mainz, Germany)
| |
Dupilumab Efficacy in Asthma Patients With FEV1 60–80% Predicted on Medium-Dose ICS: LIBERTY ASTHMA QUEST Study
A. Papi (Ferrara, Italy), I. Pavord (Oxford, United Kingdom), J. Fitzgerald (Vancouver, Canada), J. Corren (Los Angeles, United States of America), P. Bardin (Melbourne and Clayton, Australia), H. Park (Suwon, Republic of Korea), M. Rice (Cambridge, United States of America), Y. Deniz (Tarrytown, United States of America), P. Rowe (Bridgewater, United States of America), H. Staudinger (Bridgewater, United States of America), N. Amin (Tarrytown, United States of America), M. Ruddy (Tarrytown, United States of America), N. Graham (Tarrytown, United States of America), A. Teper (Bridgewater, United States of America)
| |
Dupilumab (DPL) Improves Upper and Lower Airway Outcomes in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) with Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): Pooled Results From SINUS-24, SINUS-52 Phase 3 Trials
T. Laidlaw (Boston, United States of America), J. Mullol (Barcelona, Spain), G. Canonica (Milan, Italy), C. Bachert (Ghent (Belgium) and Stockhom, Sweden), J. Han (Norfolk, United States of America), M. Zhang (Bridgewater, United States of America), X. Lu (Bridgewater, United States of America), N. Patel (Bridgewater, United States of America), N. Graham (Tarrytown, United States of America), H. Staudinger (Bridgewater, United States of America), L. Mannent (Chilly-Mazarin, France), N. Amin (Tarrytown, United States of America)
| |
Dupilumab Effect on Lung Function in Patients With Uncontrolled, Moderate-to-Severe Asthma With an Allergic Phenotype
M. Castro (Saint Louis, United States of America), J. Corren (Los Angeles, United States of America), T. Casale (Omaha, United States of America), S. Quirce (Madrid, United States of America), M. Rice (Cambridge, United States of America), Y. Deniz (Tarrytown, United States of America), P. Rowe (Bridgewater, United States of America), N. Amin (Tarrytown, United States of America), A. Teper (Bridgewater, United States of America)
| |
Clinical response to mepolizumab in patients with severe eosinophilic asthma
E. Harvey (Newcastle, Australia), D. Langton (Melbourne, Australia), H. Powell (Newcastle, Australia), P. Gibson (Newcastle, Australia)
| |
Omalizumab in allergic and non-allergic patients: results of FENOMA study
A. Mardones Charroalde (Bilbao, Spain), P. Campo Mozo (Málaga, Spain), J. Soto Campos (Jerez De La Frontera, Cádiz, Spain), A. Moreira Jorge (Barcelona, Spain), I. Dávila González (Salamanca, Spain)
| |
Efficacy of Omalizumab in adult and pediatric severe allergic asthma according to presence of multiple allergic comorbidities: evidence from the STELLAIR study.
J. Just (Paris, France), C. Thonnelier (Rueil Malmaison, France), B. Lecocq (Rueil Malmaison, France), M. Molimard (Bordeaux, France), M. Humbert (Le Kremlin-Bicêtre , France)
| |
Aspergillus sensitization and aspergillus-associated diseases in a sample of patients with severe asthma
C. Bucca (Turin, Italy), F. De Blasio (Turin, Italy), D. Dassetto (Turin, Italy), R. Ambrosanio (Turin, Italy), A. Rella (Turin, Italy), L. Riberi (Turin, Italy), P. Solidoro (Turin, Italy)
| |
Retrospective study on the combined use of voriconazole and prednisolone in the treatment of acute allergic bronchopulmonary aspergillosis (ABPA).
F. Bini (Garbagnate Milanese, Italy), D. Visca (Tradate, Italy), N. Grassi (Garbagnate Milanese, Italy), A. De Lauretis (Garbagnate Milanese, Italy), A. Spanevello (Tradate, Italy), A. Vaghi (Garbagnate Milanese, Italy)
| |
Evaluation of Airway Wall Thickness in Severe Asthma with monoclonal antibody therapy
J. Saji (Kanagawa, Japan), Y. Kanno (Kanagawa, Japan), A. Tsunoda (Kanagawa, Japan), E. Koda (Kanagawa, Japan), S. Azagami (Kanagawa, Japan), H. Muraoka (Kanagawa, Japan), M. Okamoto (Kanagawa, Japan), H. Handa (Kanagawa, Japan), H. Nishine (Kanagawa, Japan), T. Inoue (Kanagawa, Japan), T. Miyazawa (Kanagawa, Japan), M. Mineshita (Kanagawa, Japan)
| |